The Swedish company Quretech Bio has been granted a patent by the European Patent Office for a new class of synthetic antibacterial drugs under development, known as GmPcides.
GmPcides is described by the company as an innovative class of small-molecule synthetic antibiotics that combat drug-resistant bacteria, including methicillin-resistant Stap...
Quretech granted a European patent for a new type of antibiotic
The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.
Markus Thor has been the CEO of Quretech Bio since autumn 2024. Photo: Quretech Bio
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration